All In Biotech

Drug Trial Radar · NCT05838729

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Apr 3, 2023

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
Collaborators
University of Illinois Chicago
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.

Conditions

  • Head Neck Cancer
  • Intratumoral Injection

Interventions

  • RiMO-301Drug

    A single dose of RiMO-301 will be administered via an intratumoral injection. PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity. Patients will receive hypofractionated radiation in 5 fractions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of Recommended DoseTime frame: 6 weeks
  2. Evaluation of Anti-Tumor ResponseTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Illinois at Chicago

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.